Sanofi upgrades 2021 guidance once again – Dupixent drives growth

The French pharmaceutical company Sanofi has upgraded its 2021 financial guidance for earnings per share (business EPS), it reports in a press release on Thursday morning.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
New Sanofi study is yet another win for blockbuster drug
For subscribers
WHO adds Novo Nordisk insulin to essential medicine lists
For subscribers